Logo image of AVCN.CA

AVICANNA INC (AVCN.CA) Stock Fundamental Analysis

TSX:AVCN - Toronto Stock Exchange - CA05368K1003 - Common Stock - Currency: CAD

0.255  +0.01 (+2%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AVCN. AVCN was compared to 35 industry peers in the Pharmaceuticals industry. The financial health of AVCN is average, but there are quite some concerns on its profitability. AVCN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AVCN had negative earnings in the past year.
In the past year AVCN has reported a negative cash flow from operations.
AVCN had negative earnings in each of the past 5 years.
AVCN had a negative operating cash flow in each of the past 5 years.
AVCN.CA Yearly Net Income VS EBIT VS OCF VS FCFAVCN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of AVCN (-12.17%) is worse than 60.00% of its industry peers.
AVCN has a worse Return On Equity (-83.57%) than 74.29% of its industry peers.
Industry RankSector Rank
ROA -12.17%
ROE -83.57%
ROIC N/A
ROA(3y)-47.14%
ROA(5y)-65.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVCN.CA Yearly ROA, ROE, ROICAVCN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

With an excellent Gross Margin value of 53.44%, AVCN belongs to the best of the industry, outperforming 82.86% of the companies in the same industry.
In the last couple of years the Gross Margin of AVCN has grown nicely.
AVCN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.65%
GM growth 5Y8.17%
AVCN.CA Yearly Profit, Operating, Gross MarginsAVCN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

AVCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVCN has more shares outstanding than it did 1 year ago.
AVCN has more shares outstanding than it did 5 years ago.
AVCN has a better debt/assets ratio than last year.
AVCN.CA Yearly Shares OutstandingAVCN.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
AVCN.CA Yearly Total Debt VS Total AssetsAVCN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -4.54, we must say that AVCN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.54, AVCN is doing worse than 77.14% of the companies in the same industry.
AVCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.54
ROIC/WACCN/A
WACC8.71%
AVCN.CA Yearly LT Debt VS Equity VS FCFAVCN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

AVCN has a Current Ratio of 0.85. This is a bad value and indicates that AVCN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.85, AVCN is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
A Quick Ratio of 0.37 indicates that AVCN may have some problems paying its short term obligations.
AVCN's Quick ratio of 0.37 is on the low side compared to the rest of the industry. AVCN is outperformed by 82.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.37
AVCN.CA Yearly Current Assets VS Current LiabilitesAVCN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.99% over the past year.
The Revenue has grown by 14.86% in the past year. This is quite good.
Measured over the past years, AVCN shows a very strong growth in Revenue. The Revenue has been growing by 172.32% on average per year.
EPS 1Y (TTM)67.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.25%
Revenue 1Y (TTM)14.86%
Revenue growth 3Y98.2%
Revenue growth 5Y172.32%
Sales Q2Q%-1.88%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVCN.CA Yearly Revenue VS EstimatesAVCN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
AVCN.CA Yearly EPS VS EstimatesAVCN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AVCN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVCN.CA Price Earnings VS Forward Price EarningsAVCN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVCN.CA Per share dataAVCN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVCN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVICANNA INC

TSX:AVCN (6/12/2025, 7:00:00 PM)

0.255

+0.01 (+2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15
Earnings (Next)08-12 2025-08-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.33%
Ins Owner ChangeN/A
Market Cap28.11M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.11
P/FCF N/A
P/OCF N/A
P/B 9.3
P/tB 12.7
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.23
BVpS0.03
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.17%
ROE -83.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.44%
FCFM N/A
ROA(3y)-47.14%
ROA(5y)-65.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.65%
GM growth 5Y8.17%
F-Score5
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.1%
Cap/Sales 1.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.37
Altman-Z -4.54
F-Score5
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)42.25%
Cap/Depr(5y)69.89%
Cap/Sales(3y)2.21%
Cap/Sales(5y)24.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.86%
Revenue growth 3Y98.2%
Revenue growth 5Y172.32%
Sales Q2Q%-1.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.68%
OCF growth 3YN/A
OCF growth 5YN/A